IGM BIOSCIENCES INC (IGMS)

Company Profile

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 290 full-time employees. The company went IPO on 2019-09-18. The firm has created an IgM antibody technology platform for developing T cell engagers, receptor cross-linking agonists, targeted cytokines and target neutralizers. Its product candidates in clinical testing include IGM-2323 and IGM-8444. IGM-2323 is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in a Phase II clinical trial for the treatment of relapsed/refractory B cell non-Hodgkins lymphoma (NHL) patients. IGM-8444 is an IgM antibody targeting Death Receptor 5 (DR5) proteins for the treatment of patients with solid and hematologic malignancies, is in a Phase I clinical trial for the treatment of solid cancers. Its oncology pipeline also includes IGM-7354, IGM-2644 and IGM-2537.

Company Info

IGM BIOSCIENCES INC

325 E Middlefield Rd

Mountain View CALIFORNIA 94043

P: 16509657873

CEO: Fred Schwarzer

Employees: 290

Website: https://igmbio.com/